Table 2.

Comparison of clinical and pathologic features by tumor cell B7-H3 expression for 743 ccRCC patients

FeatureTumor Cell B7-H3 expression, n (%)
P
Negative, n = 614Positive, n = 129
Age at surgery (y)
    <65310 (50.5)68 (52.7)0.646
    ≥65304 (49.5)61 (47.3)
Gender
    Female221 (36.0)46 (35.7)0.943
    Male393 (64.0)83 (64.3)
Symptoms at presentation
    No237 (38.6)27 (20.9)<0.001
    Yes377 (61.4)102 (79.1)
Constitutional symptoms at presentation
    No475 (77.4)70 (54.3)<0.001
    Yes139 (22.6)59 (45.7)
ECOG performance status
    0552 (89.9)120 (93.0)0.273
    ≥162 (10.1)9 (7.0)
Tumor thrombus
    None522 (85.0)76 (58.9)<0.001
    Level 049 (8.0)26 (20.2)
    Level I-IV43 (7.0)27 (20.9)
Primary tumor size (cm)
    <5219 (35.7)19 (14.7)<0.001
    5-<7140 (22.8)18 (14.0)
    7-<10130 (21.2)35 (27.1)
    ≥10125 (20.4)57 (44.2)
2002 Primary tumor classification
    pT1a173 (28.2)6 (4.7)<0.001
    pT1b177 (28.8)25 (19.4)
    pT2126 (20.5)24 (18.6)
    pT3a44 (7.2)19 (14.7)
    pT3b83 (13.5)45 (34.9)
    pT3c6 (1.0)6 (4.7)
    pT45 (0.8)4 (3.1)
Regional lymph node involvement
    pNX and pN0597 (97.2)115 (89.2)<0.001
    pN1 and pN217 (2.8)14 (10.9)
Distant metastases
    pM0560 (91.2)101 (78.3)<0.001
    pM154 (8.8)28 (21.7)
2002 TNM stage groupings
    I336 (54.7)30 (23.3)<0.001
    II106 (17.3)17 (13.2)
    III110 (17.9)51 (39.5)
    IV62 (10.1)31 (24.0)
Nuclear grade
    150 (8.1)0<0.001
    2324 (52.8)9 (7.0)
    3218 (35.5)77 (59.7)
    422 (3.6)43 (33.3)
Coagulative tumor necrosis
    No493 (80.3)28 (21.7)<0.001
    Yes121 (19.7)101 (78.3)
Sarcomatoid differentiation
    No600 (97.7)105 (81.4)<0.001
    Yes14 (2.3)24 (18.6)